Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer
Oct 23, 2026
Read MoreZai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026
Oct 21, 2026
Read MoreZai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases
Oct 14, 2026
Read MoreZai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Sep 29, 2026
Read MoreZai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
Aug 17, 2026
Read MoreZai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates
Aug 06, 2026
Read MoreU.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)
Aug 03, 2026
Read More